Avoro Capital Advisors Reduces Its Stake in MRUS ($MRUS)

Avoro Capital Advisors no longer holds any shares of MRUS after selling its entire position.

Written by Trueearnings · Published Jun 13, 2026, 5:36 AM EDT · Updated Jun 14, 2026, 4:55 AM EDT

Key Points

Avoro Capital Advisors sold its entire stake of 3,542,500 shares in MRUS, as reported in its latest 13F filing.
Several other institutional investors, including Eversource Wealth Advisors and XTX Topco Ltd, also completely exited their MRUS positions.
Multiple analysts, including Leerink Partners and Guggenheim, downgraded MRUS to a hold rating in late 2025.

Avoro Capital Advisors has completely sold out of its position in MRUS, as shown in its recent filing with the SEC on February 17, 2026. The fund offloaded all 3,542,500 shares it previously held, marking a 100% reduction in its stake.

What Changed in Avoro Capital Advisors' MRUS Position

Avoro Capital Advisors reduced its holdings in MRUS by 3,542,500 shares, leaving it with no shares as of the filing. This move represents a complete exit from its prior position. Previously, the firm held 3,542,500 shares, indicating a full divestment.

Other Institutional Activity in MRUS

Several other institutional investors also sold out their positions in MRUS. Eversource Wealth Advisors, LLC reduced its holdings by 53 shares, ending with none. XTX Topco Ltd divested 26,768 shares, also exiting completely. Similarly, IFP Advisors, Inc, Farther Finance Advisors, LLC, NTV Asset Management LLC, and Brooklyn Investment Group each sold all their shares in MRUS, with reductions ranging from 3 to 2,452 shares.

Insider Buying and Selling at MRUS

Genmab A/S made significant insider purchases of MRUS shares in late December 2025. On December 29, Genmab A/S bought 76,920,005 shares at an average price of $97 per share. Earlier, on December 26, the company also acquired 2,978 shares and 142,610 shares, respectively, at the same price.

Analysts Set New Price Targets

In late 2025, several analysts downgraded MRUS to a hold rating. On October 6, 2025, Leerink Partners downgraded the stock, setting a price target of $97. Similarly, on September 30, Guggenheim, Canaccord Genuity, UBS, LifeSci Capital, Barclays, and HC Wainwright & Co. all issued hold ratings with the same target price. Truist Securities also downgraded the stock to hold on September 29.

Bottom Line

Avoro Capital Advisors' decision to sell all its MRUS shares is part of a broader trend among institutional investors, many of whom also exited their positions. The recent analyst downgrades to hold ratings reflect cautious sentiment around the stock. Investors will keep an eye on MRUS for any future developments, remembering that 13F filings are backward-looking and may not reflect current positions.